Drug Type Bispecific antibody |
Synonyms- |
Target |
Action inhibitors, modulators |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors), TNFR2 modulators(Tumor necrosis factor receptor superfamily member 1B modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | China | 23 Feb 2024 | |
Neoplasms | Preclinical | China | 23 Feb 2024 |